Guthrie’s Continuous Pharmaceutical Manufacturing Bill Advances
WASHINGTON, D.C. - Congressman Brett Guthrie (KY-02), Republican Leader of the Energy and Commerce Committee’s Health Subcommittee, reintroduced the National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act with Energy and Commerce Committee Chairman Frank Pallone, Jr. (D-NJ).
“A challenge for Operation Warp Speed was finding manufacturing capacity in the U.S. to quickly deliver COVID-19 vaccines. Continuous manufacturing technology is the next generation of drug manufacturing that allows for production to be more easily scaled up, which would help bring life-saving treatments to patients more quickly. The National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act gives the FDA the ability to partner with universities to further develop this technology and support its implementation. Promoting advanced and continuous manufacturing in the U.S. would create job opportunities and strengthen our drug supply chain to prevent shortages and overreliance on other countries for our prescription drug needs,” said Guthrie.
This bill would permit the Food and Drug Administration (FDA) to create partnerships with universities to support efforts to implement and further innovate continuous and advanced manufacturing technology. This emerging technology produces prescription drugs in a continuous stream and is more efficient than “batch” manufacturing techniques. Continuous manufacturing technology makes it easier to increase production, control product quality, and produce multiple doses and strengths of drugs. Investing in this technology in the United States can strengthen domestic supply chains and create jobs.
This bill was advanced from the Health Subcommittee to the full Energy and Commerce Committee for consideration.